Ontuxizumab

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameOntuxizumab
Drug Alias NameOntecizumab昂妥昔组单抗昂妥昔珠单抗M-4MORAb-004 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEndosialin inhibitors
TargetsEndosialin
Therapy Area/IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaLymphoproliferative Disorders +[32] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer ResearchMorphotek Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMorphotek IncEisai IncEisai Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaLymphoproliferative Disorders +[32] 

Other Information

ATC CodeN/A
Related LinksWikipedia